

**Publication** : The Hindu  
**Date** : December 25, 2014  
**Page** : 1 of 1  
**Title** : Torrent partners with  
Reliance Life to sell  
biosimilars in India

## Torrent partners with Reliance Life to sell biosimilars in India

### OUR BUREAU

**AHMEDABAD, DEC 25:** Ahmedabad-based Torrent Pharmaceuticals Ltd today announced that the company has entered into an exclusive licensing agreement with Reliance Life Sciences for marketing three biosimilars in the Indian market.

In an announcement made on Thursday, Torrent Pharmaceuticals informed that Rituximab, Adalimumab and Cetuximab will be developed by Reliance Life Sciences and supplied to Torrent Pharma after obtaining all necessary regulatory approvals. Torrent Pharma will be the only company to market these biosimilars in India other than Reliance Life Sciences, a company statement said here.

As per the terms of agreement, Reliance Life Sciences will manufacture these products at its facility in Navi Mumbai and supply to Torrent Pharma for a period of ten years.

Rituximab and Cetuximab cater to the oncology segment and are used in the treatment of various cancers like leukemia, lymphoma, colorectal, head and neck cancers. Adalimumab is the most preferred therapy for the treatment of auto immune disorders like rheumatoid arthritis, psoriasis and IBD.

"Torrent Pharma forayed into the oncology and dermatology segments in 2011-12 with the launch of exclusive divisions and has since gained a strong position in these segments. The licensing agreement with Reliance Life Sciences is expected to significantly boost its presence in these segments in the coming years," it said.

(This article was published on December 25, 2014)